The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking

The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking

Sponsors

Lead Sponsor: Wageningen University

Source Wageningen University
Brief Summary

The endocannabinoid (eCB) system, a neurochemical signalling system consisting of CB-receptors and their endogenous ligands, has been found to be involved in food intake of sweet and palatable foods. Activation of the eCB system increases food intake and vice versa. The mechanism behind this effect is still unknown and the current study aims at clarifying why sweet food intake increases. It is hypothesized that sweet taste intensity increases and that sweet taste is experienced as more pleasant.

Overall Status Completed
Start Date 2014-04-01
Completion Date 2015-04-16
Primary Completion Date 2015-04-16
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Relation between sweet taste intensity and liking 15 minutes after intervention
Secondary Outcome
Measure Time Frame
Ranking order of pleasantness of different drinks with different levels of sucrose. 25 minutes after intervention
Preferences for different kinds of foods 45 minutes after intervention (15 minutes after top-up dose)
Ad libitum intake 35 minutes after intervention (5 minutes after top-up dose)
Change of plasma levels of (endo-)cannabinoids and satiety hormones One hour after intervention
Polymorphisms At test session, i.e., 2 weeks before first intervention
Enrollment 10
Condition
Intervention

Intervention Type: Drug

Intervention Name: tetrahydrocannabinol

Intervention Type: Drug

Intervention Name: cannabidiol

Other Name: CBD

Intervention Type: Drug

Intervention Name: Placebo

Eligibility

Criteria:

Inclusion Criteria: - BMI: 18.5 - 25 kg/m2 - Incidental cannabis use for at least one year, at least four times per year, but less than once a week. - Dutch-speaking - Willing to comply with the study procedures - Having given written informed consent Exclusion Criteria: - Not meeting the inclusion criteria - Restraint eating (men: score > 2.90) - Lack of appetite - Having difficulties with swallowing/eating - Usage of an energy restricted diet during the last two months - Weight loss or weight gain of 5kg or more during the last two months - Stomach or bowel disease - Diabetes, thyroid disease, other endocrine disorders - Use of daily medication except paracetamol - Having taste or smell disorders (self-report) - Being allergic/intolerant for products under study - Previously experienced an adverse reaction to cannabinoids (e.g. anxiety, paranoia, nausea) - Having (had) a schizophrenia or other psychotic illness - Having a family history of schizophrenia or other psychotic illness - Working at the Division of Human Nutrition (WUR) - Current participation in other research from the Division of Human Nutrition (WUR)

Gender:

Male

Minimum Age:

18 Years

Maximum Age:

35 Years

Healthy Volunteers:

Accepts Healthy Volunteers

Overall Official
Location
Facility: Wageningen University
Location Countries

Netherlands

Verification Date

2017-05-01

Responsible Party

Type: Sponsor

Has Expanded Access No
Number Of Arms 6
Arm Group

Label: T-C-P

Type: Experimental

Description: Order of administrations: tetrahydrocannabinol - cannabidiol - placebo

Label: T-P-C

Type: Experimental

Description: Order of administrations: tetrahydrocannabinol - placebo - cannabidiol

Label: C - T - P

Type: Experimental

Description: Order of administrations: cannabidiol - tetrahydrocannabinol - placebo

Label: C - P - T

Type: Experimental

Description: Order of administrations: cannabidiol - placebo - tetrahydrocannabinol

Label: P - T - C

Type: Experimental

Description: Order of administrations: placebo - tetrahydrocannabinol - cannabidiol

Label: P - C - T

Type: Experimental

Description: Order of administrations: placebo - cannabidiol - tetrahydrocannabinol

Acronym Sweed
Study Design Info

Allocation: Randomized

Intervention Model: Crossover Assignment

Primary Purpose: Basic Science

Masking: Triple (Participant, Investigator, Outcomes Assessor)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News